MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Cue Biopharma DSO Ratio 2011-2025 | CUE
Annual DSO Ratio Cue Biopharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.9 | 58.3 | 469 | 55.7 | 164 | 79.7 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 469 | 51.9 | 146 |
Quarterly DSO Ratio Cue Biopharma
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.5 | 22.8 | - | 68.4 | 60.9 | - | 60.8 | 43.9 | 61.7 | - | 534 | 1.62 K | 186 | - | 51 | 55.2 | 83.2 | - | 184 | 120 | 110 | - | 70 | 65.3 | 93.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.62 K | 19.5 | 185 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AC Immune SA
ACIU
|
22.1 | $ 2.8 | 2.19 % | $ 229 M |  Schweiz |
 |
ADiTx Therapeutics
ADTX
|
621 | $ 2.49 | -11.39 % | $ 32.8 K |  USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
Abeona Therapeutics
ABEO
|
387 | $ 4.59 | -4.08 % | $ 98.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
55.7 | $ 12.12 | -1.58 % | $ 3.74 B | USA |
 |
Armata Pharmaceuticals
ARMP
|
249 | $ 5.37 | -20.68 % | $ 194 M | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 203.0 | -3.72 % | $ 5 B |  Danmark |
 |
Achieve Life Sciences
ACHV
|
36.8 | $ 4.64 | -0.32 % | $ 92 M | USA |
 |
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.36 | 2.73 % | $ 8.08 B |  Australia |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
82.8 | $ 54.27 | -1.38 % | $ 10.3 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Baudax Bio
BXRX
|
126 | - | 0.59 % | $ 63 K | USA |
 |
AbbVie
ABBV
|
267 | $ 224.99 | -0.01 % | $ 398 B | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
CymaBay Therapeutics
CBAY
|
182 | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
81.3 | $ 18.75 | -0.48 % | $ 2.76 B | USA |
 |
Avid Bioservices
CDMO
|
45.6 | - | - | $ 789 M | USA |
 |
BioXcel Therapeutics
BTAI
|
16.3 | $ 1.92 | -7.01 % | $ 4.87 M | USA |
 |
Biogen
BIIB
|
57.9 | $ 179.76 | 1.11 % | $ 26.2 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
AbCellera Biologics
ABCL
|
202 | $ 3.45 | -0.72 % | $ 1.02 B | Canada |
 |
Clearside Biomedical
CLSD
|
61.7 | - | - | $ 25.3 M | USA |
 |
Celsion Corporation
CLSN
|
15.6 | - | -6.63 % | $ 13.9 M | USA |
 |
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Chimerix
CMRX
|
588 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
147 | - | - | $ 401 M | USA |